In the relentless pursuit to conquer one of pediatric oncology’s most formidable adversaries, rhabdomyosarcoma, recent insights illuminate a promising frontier in targeted therapies. This malignancy, characterized by aberrant muscle cell development, reveals a complex molecular landscape, with burgeoning research spotlighting several key drivers and novel therapeutic avenues. Among these, the fibroblast growth factor receptor 4 (FGFR4) has emerged as a pivotal player, intricately linked to the oncogenic fusion proteins PAX3/7::FOXO1 and implicated in both fusion-positive and fusion-negative subtypes. This receptor’s overexpression and mutational activation set the stage for unfettered cell proliferation and metastatic progression, underscoring its significance as a targeted treatment candidate.
FGFR4’s oncogenic influence is underscored by studies demonstrating its elevated expression in primary rhabdomyosarcoma tumors relative to pediatric control tissues, correlating with advanced disease and poor patient outcomes. Crucially, activating mutations within FGFR4’s tyrosine kinase domain—namely N535K and V550L/M/E—endow the receptor with constitutive activity, propelling tumor aggressiveness and metastatic potential. These mutations, albeit present in a minority of cases, present significant challenges, as early therapeutic interventions targeting N535K have precipitated resistance, and specific inhibitors for the V550 variants remain elusive. Nevertheless, therapeutic innovation continues, with chimeric antigen receptor (CAR) T-cell therapies directed against FGFR4 advancing into clinical trials, marking a critical translation of preclinical promise into patient-focused strategies.
Yet, the journey of FGFR4-directed therapies is nuanced, as researchers grapple with the potential on-target, off-tumor effects inherent in CAR T-cell approaches. Parallel developments in antibody-drug conjugates (ADCs) targeting FGFR4 demonstrate potent preclinical activity, providing complementary modalities to immunotherapy. The intricate interplay of FGFR4 with other oncogenic pathways also guides combinatorial treatment considerations. For instance, the insulin-like growth factor 1 receptor (IGF1R), co-opted by PAX3-FOXO1, functions in a shared oncogenic transcriptional program, and clinical experience with IGF1R antibodies has revealed limited durability when used alone. Importantly, FGFR4 signaling has been shown to rescue tumor cells from IGF1R pathway inhibition, revealing an opportunity for therapeutic synergy through dual targeting of FGFR4 and IGF1R or downstream effectors such as PI3K/mTOR.
While immunotherapy and ADCs ignite optimism, alternative molecular strategies warrant exploration. The development of targeted degraders for FGFR4 holds particular allure, offering the prospect of abrogating both enzymatic and non-enzymatic scaffolding functions of the receptor, potentially mitigating drug resistance observed with kinase inhibitors. However, the complexity of rhabdomyosarcoma oncogenesis suggests these degraders will likely require combination with other agents to achieve sustained therapeutic efficacy.
Shifting focus to transcriptional drivers, MYOD1 presents a multifaceted target in rhabdomyosarcoma biology. In typical myogenesis, MYOD1 orchestrates differentiation and cell cycle exit; however, in rhabdomyosarcoma, this process is subverted. The wildtype MYOD1 in embryonal and alveolar rhabdomyosarcoma is functionally perturbed, stalling differentiation and sustaining proliferation. A particularly aggressive subset, spindle cell rhabdomyosarcoma (SCRMS), frequently harbors the MYOD1^L122R mutation—a neomorphic variant with MYC-like oncogenic properties that portends a dire prognosis. Co-occurring mutations in RAS and PI3K pathways further exacerbate tumor progression in concert with mutant MYOD1, revealing a complex network of synergistic oncogenic drivers.
Functional genomic screens underscore a universal dependency on wildtype MYOD1 across rhabdomyosarcoma subtypes, positioning it as a high-value target. Despite this, therapeutic development directly targeting MYOD1 remains nascent. The scientific community advocates for the generation of MYOD1 degraders, a strategy bolstered by preclinical data suggesting that targeting MYOD1 may selectively impair tumor cells without undue toxicity, given the partial redundancy within the myogenic transcriptional network and the tolerability observed in MYOD1 knockout models.
Another compelling molecular target is ROR2, a receptor tyrosine kinase-like orphan receptor functioning within the non-canonical WNT5A signaling axis. Unlike the canonical WNT/β-catenin pathway, which appears subordinate in rhabdomyosarcoma, ROR2 modulates cellular polarity, proliferation, and migration—processes integral to tumor invasiveness and stemness. While traditionally labeled a pseudokinase, ROR2’s capability to homodimerize and autophosphorylate upon ligand binding reveals actionable enzymatic functions, thereby offering leverage for therapeutic intervention.
Excitingly, ADCs and CAR T-cell therapies targeting ROR2 have progressed into early-phase clinical trials in other malignancies, an encouraging precedent for rhabdomyosarcoma applications. Preclinical investigations indicate that ROR2-directed ADCs could overcome therapy resistance, particularly in tumors harboring aggressive MYOD1^L122R mutants. These findings suggest avenues for therapeutic synergy with chemotherapy, thereby amplifying antitumor effects and addressing refractory disease phenotypes.
The intricate function of epigenetic regulators P300 and CBP further compounds rhabdomyosarcoma’s molecular complexity. These paralogous histone acetyltransferases interface broadly with transcription factors, modulating gene expression critical for tumor maintenance and oncogenic signaling. Notably, P300/CBP are recruited by PAX3::FOXO1 fusion proteins to potentiate oncogenic transcriptional programs, including MYOD1 activation. Emerging data reveal that inhibition of P300/CBP’s bromodomain and acetyltransferase domains impairs rhabdomyosarcoma cell viability, and the advent of degraders for these proteins presents tantalizing therapeutic options.
Among P300/CBP inhibitors, inobrodib represents the vanguard, currently navigating adult hematologic cancer trials. Despite the ubiquity and essential roles of P300/CBP in normal tissues, preclinical models demonstrate tumor cell reliance on these epigenetic factors, heralding a therapeutic window. Expanding rhabdomyosarcoma-focused preclinical assessments of P300/CBP inhibitors and degraders could unlock novel treatment paradigms, leveraging existing pharmaceutical pipelines to accelerate clinical translation.
Central to rhabdomyosarcoma’s pathobiology are the characteristic fusion proteins PAX3::FOXO1 and PAX7::FOXO1. These chimeric transcription factors commandeer extensive transcriptional programs fostering tumor growth and survival, yet their intrinsically disordered structures and nuclear localization render them notoriously refractory to conventional small molecule inhibition. Efforts harnessing antisense oligonucleotides, RNA interference, and emerging degrader technologies reveal promising attenuation of fusion protein function in vitro and in xenograft models; nevertheless, the complexity of achieving durable monotherapy responses necessitates combinatorial regimens.
Innovative modalities such as intracellular single-domain antibodies (iDAbs) offer compelling approaches to target these elusive nuclear fusions. By facilitating targeted degradation or inhibition, and enabling bispecific antibody engagement, iDAbs might circumvent the current challenges in direct fusion targeting. Similarly, immunotherapeutic strategies employing T-cell receptor-engineered T-cells confront obstacles including deficient MHC class I antigen presentation in fusion-positive tumors; however, adjunctive use of epigenetic modulators like HDAC inhibitors to upregulate antigen expression may enhance therapeutic efficacy.
Further downstream, YAP and TAZ transcriptional coactivators emerge within the Hippo signaling axis as master regulators of cell proliferation and organ size, weaving mechanical and environmental cues into gene expression control. Evidence implicates dysregulated YAP/TAZ activity in rhabdomyosarcoma progression, with elevated expression correlating variably across subtypes. Functional suppression of YAP/TAZ inhibits tumor growth and promotes differentiation, underscoring their clinical relevance.
Current therapeutic strategies focus on disrupting YAP/TAZ interaction with TEAD family transcription factors. Small molecules targeting TEAD hydrophobic pockets are advancing through early clinical stages, while novel TEAD degraders promise enhanced efficacy. Intriguingly, the intersection of Hippo and Notch pathways in rhabdomyosarcoma tumorigenesis invites combinatorial targeting approaches, with Notch inhibitors potentially abrogating upstream signals that sustain YAP/TAZ-driven transcriptional programs.
Collectively, these molecular insights signal a transformative epoch in rhabdomyosarcoma therapy. Precision-targeted strategies—ranging from receptor-directed immunotherapies to innovative degrader platforms and epigenetic modulators—hold promise for improved outcomes in this aggressive pediatric cancer. Continuing integration of cutting-edge molecular biology, clinical insights, and drug discovery efforts is paramount to surmount therapeutic resistance and advance curative treatments for children afflicted by rhabdomyosarcoma.
Subject of Research: Therapeutic target identification and development strategies in pediatric rhabdomyosarcoma
Article Title: Paediatric Therapeutic Development Workshop on rhabdomyosarcoma
Article References:
Baxter, J.S., Montiel Equihua, C., Molenaar, J.J. et al. Paediatric Therapeutic Development Workshop on rhabdomyosarcoma. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03483-1
Image Credits: AI Generated
DOI: 13 June 2026
